Immune Design reports Phase II STS data for CMB305

Immune Design Corp. (NASDAQ:IMDZ) reported interim data from a Phase II trial evaluating CMB305 plus Tecentriq atezolizumab compared to Tecentriq alone to treat soft tissue sarcoma. In a prespecified interim analysis of 36 evaluable patients, CMB305 plus Tecentriq led to a disease control rate (DCR) of 61%, including one partial response, vs. 28% and no partial responses for Tecentriq alone. Median progression-free survival (PFS) was 2.6 months for the combination arm vs. 1.4 months for Tecentriq alone.

In the full study population (n=88), CMB305 plus Tecentriq led to a DCR of 57%, including three partial responses, vs. 38% and no partial responses for Tecentriq alone. The trial enrolled patients with locally advanced, relapsed or metastatic cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-positive synovial sarcoma or myxoid/round-cell liposarcoma...